Given the considerable potential of Nav1.1 activators for Dravet syndrome and other excitability disorders, the development of small molecule Nav1.1 agonists has emerged as a rich area of investigation [102,107,108]. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.